MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Fundamental Analysis
TSX:MDP • CA58410Q2036
2.91 CAD
+0.07 (+2.46%)
Last: Feb 25, 2026, 07:00 PM
We assign a fundamental rating of 4 out of 10 to MDP. MDP was compared to 33 industry peers in the Pharmaceuticals industry. MDP has only an average score on both its financial health and profitability. MDP has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- MDP had negative earnings in the past year.
- MDP had a positive operating cash flow in the past year.
- In multiple years MDP reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: MDP reported negative operating cash flow in multiple years.
1.2 Ratios
- With a decent Return On Assets value of -0.18%, MDP is doing good in the industry, outperforming 69.70% of the companies in the same industry.
- MDP has a better Return On Equity (-0.52%) than 69.70% of its industry peers.
- The Return On Invested Capital of MDP (3.02%) is better than 72.73% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for MDP is in line with the industry average of 8.54%.
- The 3 year average ROIC (9.89%) for MDP is well above the current ROIC(3.02%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.18% | ||
| ROE | -0.52% | ||
| ROIC | 3.02% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
1.3 Margins
- MDP has a Operating Margin of 3.91%. This is in the better half of the industry: MDP outperforms 75.76% of its industry peers.
- With an excellent Gross Margin value of 53.87%, MDP belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
- In the last couple of years the Gross Margin of MDP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.91% | ||
| PM (TTM) | N/A | ||
| GM | 53.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MDP is still creating some value.
- The number of shares outstanding for MDP has been increased compared to 1 year ago.
- The number of shares outstanding for MDP has been increased compared to 5 years ago.
- Compared to 1 year ago, MDP has an improved debt to assets ratio.
2.2 Solvency
- MDP has an Altman-Z score of 0.62. This is a bad value and indicates that MDP is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 0.62, MDP is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
- The Debt to FCF ratio of MDP is 1.48, which is an excellent value as it means it would take MDP, only 1.48 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of MDP (1.48) is better than 90.91% of its industry peers.
- A Debt/Equity ratio of 0.35 indicates that MDP is not too dependend on debt financing.
- The Debt to Equity ratio of MDP (0.35) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.48 | ||
| Altman-Z | 0.62 |
ROIC/WACC0.33
WACC9.29%
2.3 Liquidity
- MDP has a Current Ratio of 1.12. This is a normal value and indicates that MDP is financially healthy and should not expect problems in meeting its short term obligations.
- The Current ratio of MDP (1.12) is worse than 78.79% of its industry peers.
- A Quick Ratio of 0.62 indicates that MDP may have some problems paying its short term obligations.
- With a Quick ratio value of 0.62, MDP is not doing good in the industry: 78.79% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.12 | ||
| Quick Ratio | 0.62 |
3. Growth
3.1 Past
- The earnings per share for MDP have decreased strongly by -112.14% in the last year.
- MDP shows a decrease in Revenue. In the last year, the revenue decreased by -9.23%.
- MDP shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.82% yearly.
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%
3.2 Future
- The Earnings Per Share is expected to grow by 53.29% on average over the next years. This is a very strong growth
- MDP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.22% yearly.
EPS Next Y-188.37%
EPS Next 2Y58.9%
EPS Next 3Y77.1%
EPS Next 5Y53.29%
Revenue Next Year-8.56%
Revenue Next 2Y3.98%
Revenue Next 3Y7.5%
Revenue Next 5Y11.22%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for MDP. In the last year negative earnings were reported.
- Based on the Price/Forward Earnings ratio of 10.51, the valuation of MDP can be described as reasonable.
- MDP's Price/Forward Earnings ratio is rather cheap when compared to the industry. MDP is cheaper than 84.85% of the companies in the same industry.
- MDP's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.03.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 10.51 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MDP indicates a rather cheap valuation: MDP is cheaper than 87.88% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, MDP is valued cheaply inside the industry as 93.94% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.01 | ||
| EV/EBITDA | 5.68 |
4.3 Compensation for Growth
- MDP's earnings are expected to grow with 77.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.9%
EPS Next 3Y77.1%
5. Dividend
5.1 Amount
- No dividends for MDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:MDP (2/25/2026, 7:00:00 PM)
2.91
+0.07 (+2.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-11 2026-02-11/amc
Earnings (Next)N/A N/A
Inst Owners3.25%
Inst Owner ChangeN/A
Ins Owners7.59%
Ins Owner ChangeN/A
Market Cap94.34M
Revenue(TTM)99.43M
Net Income(TTM)-272.00K
Analysts82.5
Price Target6.32 (117.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)54.21%
Min EPS beat(2)0.99%
Max EPS beat(2)107.43%
EPS beat(4)4
Avg EPS beat(4)77.72%
Min EPS beat(4)0.99%
Max EPS beat(4)144%
EPS beat(8)7
Avg EPS beat(8)78.39%
EPS beat(12)9
Avg EPS beat(12)100.87%
EPS beat(16)11
Avg EPS beat(16)73.38%
Revenue beat(2)0
Avg Revenue beat(2)-2.26%
Min Revenue beat(2)-4.22%
Max Revenue beat(2)-0.29%
Revenue beat(4)0
Avg Revenue beat(4)-1.39%
Min Revenue beat(4)-4.22%
Max Revenue beat(4)-0.29%
Revenue beat(8)2
Avg Revenue beat(8)-0.34%
Revenue beat(12)4
Avg Revenue beat(12)-1.11%
Revenue beat(16)7
Avg Revenue beat(16)0.69%
PT rev (1m)-0.13%
PT rev (3m)0.35%
EPS NQ rev (1m)50%
EPS NQ rev (3m)-233.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-460%
Revenue NQ rev (1m)-0.9%
Revenue NQ rev (3m)-2.29%
Revenue NY rev (1m)-0.52%
Revenue NY rev (3m)-2.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 10.51 | ||
| P/S | 0.69 | ||
| P/FCF | 4.01 | ||
| P/OCF | 3.96 | ||
| P/B | 1.32 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.68 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0.28
Fwd EY9.52%
FCF(TTM)0.73
FCFY24.94%
OCF(TTM)0.73
OCFY25.23%
SpS4.21
BVpS2.21
TBVpS-0.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.18% | ||
| ROE | -0.52% | ||
| ROCE | 4.2% | ||
| ROIC | 3.02% | ||
| ROICexc | 3.61% | ||
| ROICexgc | 107.26% | ||
| OM | 3.91% | ||
| PM (TTM) | N/A | ||
| GM | 53.87% | ||
| FCFM | 17.26% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 1.48 | ||
| Debt/EBITDA | 1.33 | ||
| Cap/Depr | 2.1% | ||
| Cap/Sales | 0.21% | ||
| Interest Coverage | 1.57 | ||
| Cash Conversion | 127.65% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.12 | ||
| Quick Ratio | 0.62 | ||
| Altman-Z | 0.62 |
F-Score5
WACC9.29%
ROIC/WACC0.33
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-112.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
EPS Next Y-188.37%
EPS Next 2Y58.9%
EPS Next 3Y77.1%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-9.23%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-15.56%
Revenue Next Year-8.56%
Revenue Next 2Y3.98%
Revenue Next 3Y7.5%
Revenue Next 5Y11.22%
EBIT growth 1Y-74.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.54%
EBIT Next 3Y65.62%
EBIT Next 5Y48.64%
FCF growth 1Y-17.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.2%
OCF growth 3YN/A
OCF growth 5YN/A
MEDEXUS PHARMACEUTICALS INC / MDP.CA FAQ
What is the ChartMill fundamental rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to MDP.CA.
What is the valuation status of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a valuation rating of 5 / 10 to MEDEXUS PHARMACEUTICALS INC (MDP.CA). This can be considered as Fairly Valued.
Can you provide the profitability details for MEDEXUS PHARMACEUTICALS INC?
MEDEXUS PHARMACEUTICALS INC (MDP.CA) has a profitability rating of 5 / 10.
What is the financial health of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
The financial health rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) is 4 / 10.